CL2019003478A1 - Forma cristalina de n-butildeoxigalactonojirimicina. - Google Patents

Forma cristalina de n-butildeoxigalactonojirimicina.

Info

Publication number
CL2019003478A1
CL2019003478A1 CL2019003478A CL2019003478A CL2019003478A1 CL 2019003478 A1 CL2019003478 A1 CL 2019003478A1 CL 2019003478 A CL2019003478 A CL 2019003478A CL 2019003478 A CL2019003478 A CL 2019003478A CL 2019003478 A1 CL2019003478 A1 CL 2019003478A1
Authority
CL
Chile
Prior art keywords
butyldeoxygalactonojirimycin
crystalline form
crystal form
butil2
hydroximethyl
Prior art date
Application number
CL2019003478A
Other languages
English (en)
Inventor
Vitor Oliveira
Ivan Pogorelic
Jean-Paul Roduit
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2019003478A1 publication Critical patent/CL2019003478A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA FORMA CRISTALINA DE [(2R, 3S, 4R, 5S) -1-BUTIL2-(HIDROXIMETIL)-PIPERIDINA-3,4,5-TRIOL, PROCESOS PARA LA PREPARACIÓN DE LA MISMA, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN DICHA FORMA CRISTALINA, Y SU USO COMO MEDICAMENTO, ESPECIALMENTE COMO INHIBIDOR DE LA BIOSÍNTESIS DE GLUCOLÍPIDOS.
CL2019003478A 2017-06-01 2019-11-28 Forma cristalina de n-butildeoxigalactonojirimicina. CL2019003478A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017063287 2017-06-01

Publications (1)

Publication Number Publication Date
CL2019003478A1 true CL2019003478A1 (es) 2020-06-05

Family

ID=62492649

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003478A CL2019003478A1 (es) 2017-06-01 2019-11-28 Forma cristalina de n-butildeoxigalactonojirimicina.

Country Status (18)

Country Link
US (2) US11306058B2 (es)
EP (1) EP3630725A1 (es)
JP (2) JP6937850B2 (es)
KR (1) KR102612650B1 (es)
CN (1) CN110799497A (es)
AU (1) AU2018278247B2 (es)
BR (1) BR112019025125A2 (es)
CA (1) CA3065147A1 (es)
CL (1) CL2019003478A1 (es)
EA (1) EA201992807A1 (es)
IL (1) IL270961A (es)
MA (1) MA48944A (es)
MX (1) MX2019014427A (es)
MY (1) MY201196A (es)
PH (1) PH12019502635A1 (es)
TW (1) TWI770184B (es)
UA (1) UA125938C2 (es)
WO (1) WO2018220131A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3065147A1 (en) * 2017-06-01 2018-12-06 Idorsia Pharmaceuticals Ltd Crystalline form of n-butyldeoxygalactonojirimycin
US20220411371A1 (en) 2019-09-25 2022-12-29 Teva Pharmaceuticals International Gmbh Solid state forms of lucerastat and process for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000277A1 (fr) * 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB0229476D0 (en) 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2006037069A1 (en) 2004-09-28 2006-04-06 Allergan, Inc. Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
KR20080033463A (ko) 2005-07-27 2008-04-16 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도
JP2009538276A (ja) 2006-04-24 2009-11-05 アカデミッシュ メディシュ セントラム 嚢胞性線維症の改良型治療
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
ITMI20122090A1 (it) 2012-12-06 2014-06-07 Dipharma Francis Srl Sintesi di un inibitore delle glicosiltransferasi
CA3065147A1 (en) * 2017-06-01 2018-12-06 Idorsia Pharmaceuticals Ltd Crystalline form of n-butyldeoxygalactonojirimycin

Also Published As

Publication number Publication date
IL270961A (en) 2020-01-30
CA3065147A1 (en) 2018-12-06
TW201902876A (zh) 2019-01-16
BR112019025125A2 (pt) 2020-07-21
WO2018220131A1 (en) 2018-12-06
JP6937850B2 (ja) 2021-09-22
US20200140385A1 (en) 2020-05-07
MA48944A (fr) 2020-04-08
UA125938C2 (uk) 2022-07-13
MX2019014427A (es) 2020-02-05
EP3630725A1 (en) 2020-04-08
KR102612650B1 (ko) 2023-12-11
MY201196A (en) 2024-02-09
JP7373529B2 (ja) 2023-11-02
US11306058B2 (en) 2022-04-19
AU2018278247B2 (en) 2022-07-28
TWI770184B (zh) 2022-07-11
JP2021185184A (ja) 2021-12-09
US20220002245A1 (en) 2022-01-06
EA201992807A1 (ru) 2020-05-20
PH12019502635A1 (en) 2020-07-13
US11713297B2 (en) 2023-08-01
AU2018278247A1 (en) 2020-01-16
KR20200011992A (ko) 2020-02-04
JP2020521796A (ja) 2020-07-27
CN110799497A (zh) 2020-02-14

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
ECSP18014922A (es) Composiciones de insulina de rápida acción
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
DOP2016000253A (es) Nuevos compuestos
BR112016006048A8 (pt) composições antimicrobianas
EP3613419A4 (en) PHARMACEUTICAL COMPOSITION WITH INDIRUBY DERIVATIVE AS THE ACTIVE SUBSTANCE
EP4327880A3 (en) Solid state form of ribociclib succinate
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
MX355831B (es) NOVEDOSOS HIDRATOS CRISTALINOS DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3 -[5-(4-FLUORO-FENIL)-2-TIENIL-METIL]-BENCENO.
BR112012009310B8 (pt) composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
CU20190079A7 (es) Compuestos derivados de 3-([2-fenoxi]fenoxi)-2-hidroxi-n-bencyl-ciclohexilamina substituidos como inhibidores de la función mitocondrial y composiciones farmacéuticas que los contienen
EP4066835A4 (en) USE OF A COMPOSITION FOR INCREASE ANTI-CANCER EFFECT HAVING A GAMMA INHIBITOR AS THE ACTIVE INGREDIENT
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2019003478A1 (es) Forma cristalina de n-butildeoxigalactonojirimicina.
BR112017014996A2 (pt) formulações farmacêuticas e recipientes selados
BR112018012043A2 (pt) processo para a redução da transpiração
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112017012930A2 (pt) derivados de imidazopiridazina como inibidores de pi3kbeta.
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
BR112017013031A2 (pt) derivados de imidazopiridazina ligados à heterociclila como inibidores de pi3kbeta